Payment overview · 2025
General Payments
$769.11
39 reported records · 18 companies
Healthcare provider profile · identity verified
Gilberto Luis Vigo, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · PENSACOLA, FL · NPI 1790760502
Verified facts
What the public records show
CMS Open Payments records show Gilberto Luis Vigo, M.D. received $769.11 in general payments during 2025 across 39 reported records.
PFIZER INC. accounted for 15.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta, Trintellix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 184 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 185 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 277 claims for Eliquis by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $115.16 | 15.0% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $67.49 | 8.8% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $64.60 | 8.4% | 4 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $64.49 | 8.4% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $59.65 | 7.8% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $57.40 | 7.5% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $48.60 | 6.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $46.81 | 6.1% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $46.69 | 6.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $43.33 | 5.6% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $23.56 | 3.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.95 | 3.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.33 | 2.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $21.75 | 2.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.63 | 2.7% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $17.16 | 2.2% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $16.51 | 2.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $10.00 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $769.11 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $93.83 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $67.49 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $64.60 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $64.60 | 4 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $64.49 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $58.48 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $57.40 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $48.60 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $43.33 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $43.33 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $35.35 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $32.83 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $31.94 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.94 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $31.83 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $26.82 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $23.56 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $23.56 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.95 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $22.33 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $21.75 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $21.33 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $21.33 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $21.33 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $20.63 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $17.16 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $16.51 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.98 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $14.98 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.98 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.75 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $10.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 277 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 60 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 184 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 185 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 97 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
51 | 16 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
24 | 20 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
60 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
97 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
60 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
184 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
139 | 30 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
185 | 45 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
277 | 50 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1047 | 272 |
| Levothyroxine Sodium | Levothyroxine Sodium | 757 | 191 |
| Amlodipine Besylate | Amlodipine Besylate | 569 | 147 |
| Alprazolam | Alprazolam | 409 | 71 |
| Potassium Chloride | Potassium Chloride | 405 | 93 |
| Losartan Potassium | Losartan Potassium | 357 | 98 |
| Gabapentin | Gabapentin | 332 | 87 |
| Omeprazole | Omeprazole | 327 | 96 |
| Furosemide | Furosemide | 310 | 82 |
| Pantoprazole Sodium | Pantoprazole Sodium | 309 | 95 |
| Metoprolol Succinate | Metoprolol Succinate | 299 | 90 |
| Lisinopril | Lisinopril | 296 | 80 |
| Eliquis | Apixaban | 277 | 50 |
| Ezetimibe | Ezetimibe | 268 | 68 |
| Clopidogrel | Clopidogrel Bisulfate | 265 | 67 |
| Trazodone Hcl | Trazodone Hcl | 239 | 64 |
| Lorazepam | Lorazepam | 236 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 236 | 56 |
| Metformin Hcl | Metformin Hcl | 218 | 59 |
| Sertraline Hcl | Sertraline Hcl | 205 | 52 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 197 | 60 |
| Atenolol | Atenolol | 189 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 187 | 46 |
| Zolpidem Tartrate | Zolpidem Tartrate | 186 | 26 |
| Ozempic | Semaglutide | 185 | 45 |
| Mounjaro | Tirzepatide | 184 | 37 |
| Tramadol Hcl | Tramadol Hcl | 179 | 36 |
| Clonazepam | Clonazepam | 177 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 162 | 52 |
| Fluticasone Propionate | Fluticasone Propionate | 159 | 60 |
| Terazosin Hcl | Terazosin Hcl | 155 | 45 |
| Finasteride | Finasteride | 152 | 42 |
| Prednisone | Prednisone | 152 | 59 |
| Donepezil Hcl | Donepezil Hcl | 150 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 149 | 46 |
| Glimepiride | Glimepiride | 147 | 47 |
| Montelukast Sodium | Montelukast Sodium | 144 | 48 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 140 | 32 |
| Trulicity | Dulaglutide | 139 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 138 | 42 |
| Clonidine Hcl | Clonidine Hcl | 131 | 43 |
| Allopurinol | Allopurinol | 127 | 36 |
| Estradiol | Estradiol | 127 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 125 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 121 | 43 |
| Spironolactone | Spironolactone | 121 | 29 |
| Celecoxib | Celecoxib | 119 | 43 |
| Nifedipine Er | Nifedipine | 118 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 116 | 40 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 116 | 33 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 113 | 29 |
| Carvedilol | Carvedilol | 110 | 30 |
| Ondansetron Hcl | Ondansetron Hcl | 110 | 31 |
| Xarelto | Rivaroxaban | 110 | 16 |
| Famotidine | Famotidine | 109 | 33 |
| Simvastatin | Simvastatin | 103 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 100 | 23 |
| Memantine Hcl | Memantine Hcl | 100 | 18 |
| Mirtazapine | Mirtazapine | 97 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 97 | 25 |
| Bupropion Xl | Bupropion Hcl | 96 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 92 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 91 | 24 |
| Amitriptyline Hcl | Amitriptyline Hcl | 88 | 29 |
| Meloxicam | Meloxicam | 87 | 30 |
| Fenofibrate | Fenofibrate | 86 | 21 |
| Nystatin | Nystatin | 82 | 39 |
| Temazepam | Temazepam | 81 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 80 | 27 |
| Divalproex Sodium | Divalproex Sodium | 79 | 18 |
| Levetiracetam | Levetiracetam | 79 | 11 |
| Clonidine | Clonidine | 78 | 13 |
| Lovastatin | Lovastatin | 78 | 20 |
| Metformin Hcl Er | Metformin Hcl | 78 | 22 |
| Buspirone Hcl | Buspirone Hcl | 77 | 29 |
| Doxycycline Hyclate | Doxycycline Hyclate | 73 | 38 |
| Tresiba Flextouch U-100 | Insulin Degludec | 66 | 13 |
| Azithromycin | Azithromycin | 65 | 43 |
| Chlorthalidone | Chlorthalidone | 65 | 21 |
| Rivastigmine | Rivastigmine Tartrate | 65 | 18 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 63 | 17 |
| Candesartan Cilexetil | Candesartan Cilexetil | 63 | 21 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 63 | 14 |
| Repatha Sureclick | Evolocumab | 63 | 18 |
| Warfarin Sodium | Warfarin Sodium | 63 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 62 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 62 | 16 |
| Baclofen | Baclofen | 61 | 12 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 61 | 19 |
| Ramipril | Ramipril | 61 | 16 |
| Jardiance | Empagliflozin | 60 | 16 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 58 | suppressed |
| Sucralfate | Sucralfate | 57 | 29 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 54 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 53 | 19 |
| Ibandronate Sodium | Ibandronate Sodium | 52 | 19 |
| Synthroid | Levothyroxine Sodium | 51 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 51 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 50 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 48 | 39 |
| Diazepam | Diazepam | 48 | suppressed |
| Eszopiclone | Eszopiclone | 48 | 13 |
| Januvia | Sitagliptin Phosphate | 48 | suppressed |
| Primidone | Primidone | 48 | 13 |
| Alendronate Sodium | Alendronate Sodium | 47 | 13 |
| Fluconazole | Fluconazole | 47 | 30 |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | 15 |
| Myrbetriq | Mirabegron | 46 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 46 | 11 |
| Valsartan | Valsartan | 46 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 45 | 28 |
| Aripiprazole | Aripiprazole | 44 | suppressed |
| Irbesartan | Irbesartan | 44 | 12 |
| Calcitriol | Calcitriol | 42 | 13 |
| Methylprednisolone | Methylprednisolone | 42 | 37 |
| Ranolazine Er | Ranolazine | 42 | suppressed |
| Entresto | Sacubitril/Valsartan | 41 | suppressed |
| Minoxidil | Minoxidil | 40 | 11 |
| Azelastine Hcl | Azelastine Hcl | 39 | 22 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | 11 |
| Folic Acid | Folic Acid | 38 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 37 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | 11 |
| Pregabalin | Pregabalin | 36 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 34 | 11 |
| Torsemide | Torsemide | 34 | 11 |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 33 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 26 |
| Nortriptyline Hcl | Nortriptyline Hcl | 31 | suppressed |
| Diclofenac Sodium-Misoprostol | Diclofenac Sodium/Misoprostol | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | 16 |
| Nebivolol Hcl | Nebivolol Hcl | 30 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 29 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 29 | suppressed |
| Linzess | Linaclotide | 29 | suppressed |
| Telmisartan | Telmisartan | 29 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 29 | 12 |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 28 | suppressed |
| Triazolam | Triazolam | 28 | suppressed |
| Nitroglycerin | Nitroglycerin | 27 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 27 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Lactulose | Lactulose | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 13 |
| Ondansetron Odt | Ondansetron | 26 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | suppressed |
| Methocarbamol | Methocarbamol | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Prolia | Denosumab | 24 | 20 |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 22 | suppressed |
| Fetzima | Levomilnacipran Hcl | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 21 | suppressed |
| Metolazone | Metolazone | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 20 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 11 |
| Diltiazem Hcl | Diltiazem Hcl | 19 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 19 | suppressed |
| Levetiracetam Er | Levetiracetam | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | 14 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Creon | Lipase/Protease/Amylase | 17 | suppressed |
| Klor-Con 10 | Potassium Chloride | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 17 | suppressed |
| Misoprostol | Misoprostol | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 16 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Buprenorphine | Buprenorphine | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Febuxostat | Febuxostat | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Budesonide | Budesonide | 12 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Alprazolam Er | Alprazolam | 11 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $769.11 · 39 records | PFIZER INC. | ABRYSVO, AIRSUPRA, AREXVY, Auvelity, BEXSERO, CAPLYTA, COMIRNATY, CONTRAVE, ELIQUIS, EVENITY, FREESTYLE LIBRE 3, JARDIANCE, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, SHINGRIX, Symbravo, TRELEGY ELLIPTA, TRINTELLIX, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, Veozah, XIFAXAN, ZAVZPRET, ZEPBOUND | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error